The presence or absence of galactorrhoea does not seem to be related to dose requirement, but the differences between the other groups are statistically highly significant.
Fig 1 shows clearly that although the mean doses in the two diagnostic categories are significantly different, there is a considerable range of individual means in each group (approximately 5 to 1) and an overlap between the groups. For this reason, the diagnostic category of the patient will give only some initial guidance to treatment. The need to individualize treatment remains.
The aim of treatment is to reproduce the normal physiological maturation of the follicle and then to give chorionic gonadotrophin as a source of LH activity to induce ovulation and corpus luteum formation. Recent investigations by Fukushima et al. (1964) and other groups into the excretion of FSH and LH during the normal ovulatory cycle have suggested that FSH may be required only for a few days at the beginning of the cycle. In addition we now know that the maximum cestrogenic response occurs five to eight days after a single injection of FSH, or after eleven to twelve days if HCG is combined with the FSH dose. This information has cast doubt upon the rationale of eight to ten day courses of FSH and has prompted Crooke and others to attempt ovulation induction with a single dose of FSH, followed by HCG eight or ten days later. We now know that this is an effective regime and there are good reasons for believing that it may lead to a lower incidence of hyperstimulation including multiple pregnancy. A study of the optimum treatment of infertile amenorrhceic patients with human folliclestimulating hormone (FSH) and chorionic gonadotrophin (HCG) requires the investigation of a number of variables. These include variations between patients, between dosage, number of injections and length of treatment with FSH and the same with HCG and variations in the timing of treatment with HCG in relation to FSH. In our experiments responses were assessed by increases in excretion of cestriol and of pregnanediol using formal statistical designs (Crooke et al. 1963) .
Several interesting facts emerged. The best responses occurred with 24,000 i.u. HCG given as a single injection two days after the last dose of FSH. When the total dose of FSH was given as a single injection or divided into 2, 4 or 8 equal injections a good linear relationship between response and number of injections was demonstrated, a single injection being twice as effective as eight. Although patients showed a striking increase in excretion of cestriol with one or two injections there was no corresponding increase in excretion of pregnanediol, indicating that ovulation had failed to occur and it was necessary with this design to give a minimum of three equal injections of FSH over eight days followed by HCG on the tenth (Crooke et al. 1964) . This became our standard treatment up to two years ago.
The variations between patients were examined by determining their median effective doses (ED50). These varied by at least sevenfold between patients and a dose-response curve was established (Crooke et al. 1966a ). This is shown by line A in Fig 1 which records the probability that a positive cestriol response will occur with any given dosage expressed as a percentage of the ED50. Line B represents those dosages at which ovulation occurred as judged by an increase in excretion of pregnanediol. Line C represents the dosages at which pregnancy occurred and line D the dosages at which excessive responses occurred but there were only 3 cases of mild 'hyperstimulation syndrome' in 140 months of treatment. A sensitivity test was then developed using a single injection of FSH and increasing the dosage at regular intervals until a positive response occurred. Recently this has been followed by treatment with HCG given on the ninth day after the FSH (Crooke et al. 1966b) in this way test doses and treatment can be combined and may result in ovulation. No case of 'hyperstimulation syndrome' has occurred in the past two years since test doses have been introduced.
With standard treatment of three injections of FSH over eight days a total dose one and a half times as great as the single effective test dose was used to produce a similar effect. This dose-effect relationship has now been re-examined in a group of 4 patients treated for four months each, either with single injections or three injections of FSH over eight days followed by 24,000 i.u. HCG on the tenth. The total dose of FSH with three injections was invariably one and a half times as great as that given with a single injection. Fig 2 sum marizes the results. There is no significant difference in the responses between the two forms of treatment which confirms the earlier observations.
The dosage and timing of treatment with HCG was re-examined next in another experiment with 4 patients. In two months each patient was given FSH mixed with 12,000 i.u. HCG and the other two months FSH alone. They were all given HCG on the tenth day, but in two months the dose was 24,000 i.u. and in the other two it was 4,000 i.u. Again there was no significant difference in response between treatments showing that HCG need not be mixed with FSH and that 4,000 i.u. HCG on Day 10 is adequate. The unsatisfactory response when lower doses of HCG were used in the earlier experiments was probably due to the relatively lower doses of FSH then used. Human pituitary FSH is readily administered as a single injection: equivalent dosages of commercial preparations of urinary FSH would necessitate the use of large numbers of ampoules. Finally, therefore, a comparison was made between responses to single injections with responses to the same dose given in three equal injections on successive days. The differences were not significant showing that commercial preparations can be satisfactorily given in divided doses on three successive days. The dosage schedule now used is given in Table 1. Ampoules of the commercial preparation Pergonal each contain 75 i.u. FSH, and up to 21 ampoules will readily dissolve in a total of 2 ml solvent. If another 1 ml solvent is then used to wash out each ampoule in succession and the combined 3 ml injected the total loss of FSH is not greater than 5 %. We believe that this is the safest, simplest and most economical method of treatment with human gonadotrophins.
